Ben Samelson-Jones, MD, PhD

Articles by Ben Samelson-Jones, MD, PhD

Conservative Management Following Treatment With DMD Gene Therapy Elevidys

ByBen Samelson-Jones, MD, PhD,Noah Stansfield

May 19th 2025

Ben Samelson-Jones, MD, PhD, the associate director of clinical in vivo gene therapy at Children’s Hospital of Philadelphia discussed a case he presented at the American Society of Gene and Cell Therapy’s 2025 meeting.

Ben Samelson-Jones, MD, PhD, on Conservative Management Following Treatment With DMD Gene Therapy Elevidys

ByBen Samelson-Jones, MD, PhD,Noah Stansfield

May 16th 2025

The associate director of clinical in vivo gene therapy at Children’s Hospital of Philadelphia discussed a case he presented at the American Society of Gene and Cell Therapy’s 2025 meeting.

Confirming the Safety of Pfizer's Hemophilia B Gene Therapy Beqvez

ByBen Samelson-Jones, MD, PhD,Noah Stansfield,Victoria Johnson

December 22nd 2024

Ben Samelson-Jones, MD, PhD, the associate director of clinical in vivo gene therapy at Children’s Hospital of Philadelphia, discussed follow-up data of up to 6 years with investigations of fidanacogene elaparvovec.

Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia

Ben Samelson-Jones, MD, PhD, on Confirming the Safety of Pfizer's Hemophilia B Gene Therapy Beqvez

ByBen Samelson-Jones, MD, PhD,Victoria Johnson

December 13th 2024

The associate director of clinical in vivo gene therapy at Children’s Hospital of Philadelphia discussed follow-up data of up to 6 years with investigations of fidanacogene elaparvovec.